EMERYVILLE, Calif.--(BUSINESS WIRE)--Lucira Health, an innovator of rapid, molecular, point-of-care infectious disease tests, has been renamed from Diassess Inc as it develops a new class of professional and home-health solutions to help elucidate and illuminate healthcare decision-making.
“We are excited to take the next step in our growth as we plan for the FDA submission and subsequent commercial launch of our influenza testing products,” said Erik Engelson, Chief Executive Officer at Lucira Health. “Influenza is an annual problem. To the extent that patients can be treated or isolated at the first sign of infection, the spread of disease may be mitigated. At Lucira Health, we aim to empower physicians and consumers to take action at the first sign of infection in both the clinic and the home.”
Founded in 2013, Lucira Health is applying its expertise to develop and commercialize rapid DNA-based diagnostic tools for infectious diseases such as respiratory illnesses, sexually transmitted infections and others. Lucira Health’s flu-diagnostic technologies give healthcare professionals and consumers a highly accurate diagnosis within 20 minutes. Beginning with a nasal swab, the sample is inserted into a disposable DNA test. The battery-powered device quickly analyzes the sample and a digital readout indicates either influenza A, B, or a negative diagnosis. The in-home version will use a smartphone application to directly connect the consumer to treatment options.